Product Information
- MED 14736
- Immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 κ-chain, dimer
- MEDI 4736
- Immunoglobulin G1, anti-(human protein B7-H1) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 κ-chain, dimer
Durvalumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds to PD-L1, a protein expressed on the surface of tumor cells. Durvalumab is being studied in combination with tremelimumab (another anti-PD-L1 antibody) for use as an antitumor agent. The combination of durvalumab and tremelimumab has been shown to have an antitumor response in mice with bowel disease. This drug has been shown to have an immune-modulating effect in combination therapy groups.
Chemical properties
Technical inquiry about: 3D-DHC93560 Durvalumab
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.